Funding community collaboration to develop effective therapies for neurofibromatosis type 1 tumors | EMBO Molecular Medicine
MOA | Study Design | KOSELUGO® (selumetinib) 10 mg & 25 mg capsules | For HCPs
Koselugo (selumetinib) for the Treatment of Neurofibromatosis Type 1
_(1).png "First Drug Approved for NF | Children's Tumor Foundation")
First Drug Approved for NF | Children's Tumor Foundation
EU approves Koselugo for treatment of plexiform neurofibromas
Children's Tumor Foundation - NF News Spring 2020 by Children's Tumor Foundation - Issuu
Dramatic Improvement of a Massive Plexiform Neurofibroma After Administration of Selumetinib - Pediatric Neurology
NF1 Clinical Trial of Selumetinib “Most Exciting” Says National Cancer Institute Director | Children's Tumor Foundation
Selumetinib granted orphan drug designation in Japan for NF1 - Nordic Life Science – the leading Nordic life science news service
Phase 2 Trial Shows Selumetinib Shrinks Nerve Tumors in Children With NF1 | Technology Networks
Activity of Selumetinib in Neurofibromatosis Type 1–Related Plexiform Neurofibromas | NEJM
In NIH trial, selumetinib shrinks tumors, provides clinical benefit for children with NF1 | National Institutes of Health (NIH)
Clinical Pharmacokinetics and Pharmacodynamics of Selumetinib | SpringerLink
Selumetinib improves outcomes for children with NF1 - NCI
Funding community collaboration to develop effective therapies for neurofibromatosis type 1 tumors | EMBO Molecular Medicine
Clinical and Experimental Pediatrics
AZ's Koselugo scores regulatory nod for children with rare neurofibroma < Pharma < 기사본문 - KBR
A melanoma drug shows promise for NF1 plexiforms | Children's National
First Drug Approved for NF | Children's Tumor Foundation
Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. | Semantic Scholar
Selumetinib enhances the anti-migratory effects of LDN-193189 in MPNST... | Download Scientific Diagram
Activity of Selumetinib in Neurofibromatosis Type 1–Related Plexiform Neurofibromas | NEJM
NIH trial shows selumetinib shrinks tumors, provides clinical benefit for children with NF1 | Healthcare Purchasing News
Selumetinib in Children with Inoperable Plexiform Neurofibromas | NEJM
